Additionally, there are baseline differences between the PC and AC groups, mainly due to stroke etiology, use of IV-tPA, and longer times to treatment in the PC group, the latter of which we attribute to the inherent challenge of treating PC strokes. This evidence concerns the gene PLAT and stroke disorder.